secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-06-18T23:59:59+00:00
Accession:  0000950170-24-074846
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics stockholders elect two Class I directors, ratify EY as auditor
--------------------------------------------------------------------------------

- Paul A. Friedman, M.D. elected as Class I director with 31,165,370 votes for, 1,762,716 withheld.
- David P. Bonita, M.D. elected as Class I director with 31,007,172 votes for, 1,920,914 withheld.
- Ratification of Ernst & Young LLP as independent auditor for FY2024: 34,994,229 for, 57,512 against, 14,440 abstaining.
- Broker non-votes of 2,138,095 on director elections; none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024074846/0000950170-24-074846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024074846/prld-20240614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-074846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer